# Atropine for neonates

## **BRIEF ADMINISTRATION GUIDE**

For detailed information refer to The Australasian Neonatal Medicines Formulary atropine guideline

Note: Shaded text indicates where Te Whatu Ora Waikato practice differs from ANMF

### 1. Medicine

### 1.1. Indications

- Prevention of reflex bradycardia during elective endotracheal intubation
- Premedication to prevent perioperative adverse events

#### 1.2. Route and Presentation

Intravenous (preferred) or intramuscular (if IV not available)

**Note:** Absorption and time to peak heart rate effect is slower compared to IV when atropine is given IM therefore not the preferred route in an emergency

- Supplied as atropine sulphate 600 microgram per 1 mL ampoule
  - pH 2.8 4.5

#### 1.3. Dose

20 microgram/kg (range 10-20 microgram/kg)

Dose may be repeated every 10-15 minutes to achieve desired effect, with a maximum total dose of 40 microgram/kg

## 2. Preparation and Administration

### 2.1. Compatible fluids

Sodium chloride 0.9%

### 2.2. Administration Method

#### Intravenous

- Dilute 1mL ampoule with 5mL of sodium chloride 0.9% to produce a 100 microgram/mL solution (600 microgram / 6 mL)
- Note: can be administered undiluted (if accurate dose measurement possible)
- Draw up prescribed dose and administer as a slow push

#### Intramuscular

<3kg: dilute as above (final concentration 100 microgram/mL)

>3kg: consider undiluted administration (600 microgram/mL)

• Draw up prescribed dose of atropine and give intramuscularly

### 2.3. Monitoring

Monitor heart rate continuously

2.4. Storage and Stability

Discard any unused contents of the ampoule remaining

### 2.5. Competency for Administration

This procedure is carried out by, or under, the direct supervision of a registered nurse/registered midwife who holds current Te Whatu Ora Waikato Generic Medicine Management and IV certification. For CVAD administration Neonatal specific competency NCV/NAC is also required.

### 2.6. Guardrails

N/a

Doc ID:	6356	Version:	2	Date Created:	MAR 2023	Review Due:	MAR 2026
IF THIS DOCUMENT IS PRINTED, IT IS VALID ONLY FOR THE DAY OF PRINTING						Page 1 of 2	

# Atropine for neonates

# 3. References

- Australian Neonatal Medicines Formulary. Atropine Drug Guideline 2021. Available from: <u>https://www.anmfonline.org/clinical-resources/</u>
- New Zealand Formulary for Children (NZFC) v119. Atropine. Available from: <u>https://nzfchildren.org.nz/nzf\_6931</u>
- Truven Health Analytics Inc. Pediatrics and Neofax<sup>®</sup>. Atropine monograph. Accessed June 2020. Available from: <u>http://www.micromedexsolutions.com.</u>
- Phelps SJ, Hagemann TM, Lee KR, Thompson AJ. The Teddy Bear Book: Pediatric Injectable Drugs. 11th edition. American Society of Health-System Pharmacists; 2018.
- The Royal Children's Hospital Melbourne. Paediatric Injectable Guidelines. Accessed May 2022. Available from: https://pig.rch.org.au/monographs/atropine/
- Auckland DHB Newborn Services. Atropine Sulphate Drug Protocol. August 1998. Available from <a href="https://starship.org.nz/guidelines/atropine-sulphate/">https://starship.org.nz/guidelines/atropine-sulphate/</a>
- Canterbury DHB Neonatal Services. Atropine sulphate Drug Information Sheet. Accessed May 2022. Available from
  <u>https://edu.cdhb.health.nz/Hospitals-Services/Health-Professionals/Neonatal-Clinical-Resources/Neonatal-Drug-Information-Sheets/Documents/Atropine-236654.pdf</u>
- Queensland Health Atropine guideline. Accessed May 2022 via <u>https://www.health.qld.gov.au/\_\_\_\_\_\_data/assets/pdf\_\_file/0032/846842/nmq-atropine.pdf</u>
- Notes on Injectable Drugs. NZ Hospital Pharmacists Assoc. 2020. Accessed on 30<sup>th</sup> May 2022 via <u>www.noids.nz/wp-content/uploads/2020/11/Atropine-sulfate-S.pdf</u>

Document Ownership							
Document Authorisor:	John Barnard	Chair Medicines & Therapeutics Committee					
Document Authorisor:	Jutta van den Boom	Clinical Director Neonatal Intensive Care Unit					
Document Facilitator:	Kerrie Knox	Pharmacist					
Disclaimer: This document has been developed by Te Whatu Ora Waikato specifically for its own use. Use of this document and any reliance on the							

**Disclaimer:** This document has been developed by Te Whatu Ora Waikato specifically for its own use. Use of this document and any reliance on the information contained therein by any third party is at their own risk and Te Whatu Ora Waikato assumes no responsibility whatsoever.

Doc ID:	6356	Version:	2	Date Created:	MAR 2023	Review Due:	MAR 2026
IF THIS DOCUMENT IS PRINTED, IT IS VALID ONLY FOR THE DAY OF PRINTING							Page 2 of 2